eTable 6. Infant-Level Clinical Examination Findings at the 12-Month Outcome Exam

	Total Dose of Bevacizumab Injected Into Both Eyes Prior to 12-Months										
	Overall N=98 <sup>a</sup>		0.1875 to		0.016 to						
			>=0.50mg N=22 <sup>a</sup>		0.375 mg N=29 <sup>a</sup>		0.09375 mg N=23 <sup>a</sup>		<=0.	.012mg	
									N=24a		1
	n	%	n	%	n	%	n	%	n	%	P-Value
Ocular Alignment at Distance											
Constant strabismus	5	5%	0	0%	2	7%	2	9%	1	4%	
Intermittent strabismus	4	4%	0	0%	1	3%	1	4%	2	8%	
Orthotropic	58	59%	12	55%	19	66%	16	70%	11	46%	-
Unable	26	27%	10	45%	7	24%	4	17%	5	21%	
Not Done	5	5%	0	0%	0	0%	0	0%	5	21%	
Ocular Alignment at Near											
Constant strabismus	11	11%	0	0%	6	21%	4	17%	1	4%	
Intermittent strabismus	17	17%	4	18%	6	21%	5	22%	2	8%	
Orthotropic	63	64%	17	77%	17	59%	13	57%	16	67%	-
Unable	2	2%	1	5%	0	0%	1	4%	0	0%	
Not Done	5	5%	0	0%	0	0%	0	0%	5	21%	
<b>Constant or Intermittent Strabismus at</b>											
Distance or Near?	28	29%	4	18%	12	41%	9	39%	3	13%	.86 <sup>b</sup>
Manifest Nystagmus Present?	12	12%	5	23%	2	7%	3	13%	2	8%	.50 <sup>b</sup>
Amblyopia Present?	7	7%	2	9%	2	7%	2	9%	1	4%	1.0°
Anisometropia <sup>d</sup>											
(Spherical Equivalent)											
Refraction not done	7	7%	1	5%	0	0%	1	4%	5	21%	
0.00D	33	34%	6	27%	15	52%	6	26%	6	25%	
>0.00D to <=1.50D	42	43%	10	45%	11	38%	12	52%	9	38%	
>1.50D	15	15%	5	23%	2	7%	4	17%	4	17%	
Mean (SD)	1.02D (1.99D)		1.48D (2.75D)		0.76D (2.01D)		1.18D (1.85D)		0.72D (0.85D)		
Median	0.44D		0.50D		0.00D		0.50D		0.25D		
Quartiles	0.00D,1.13D		0.00D,1.00D		0.00D, 0.56D		0.00D,1.25D		0.00D,1.25D		
Range	0.00D to 12.00D		0.00D to 12.00D		0.00D to 10.50D		0.00D to 6.75D		0.00D to 2.50D		.47e

CI = Confidence Interval

<sup>&</sup>lt;sup>a</sup> Number of infants treated initially with bevacizumab examined at the 12-month exam. Total dose of bevacizumab grouped into quartiles.

<sup>&</sup>lt;sup>b</sup> P-value from logistic regression between the binary outcome and log total patient dose as a continuous factor.

<sup>&</sup>lt;sup>c</sup> Since limited number of outcomes, P-value from Fisher's Exact test for an association between the binary outcome and total dose as a categorical factor.

<sup>&</sup>lt;sup>d</sup> Excludes 1 patient with aphakia.
<sup>e</sup> P-value from linear model for an association between the continuous outcome and total dose as a categorical factor.